S
In Pk/Pd modeling, in a mouse-thigh model using S
Not a preferred agent for CAP
Linezolid may be an option for severe group A Streptococcus (GAS) infections based on its potent in vitro activity and antitoxin effects, but clinical data
It will not
#3/3) MRSA coverage, preferably with linezolid Linezolid was superior to vancomycin in a Cochrane review of skin and soft tissue infections
Actinomycosis: 600 mg IV q 8h x 2-6 weeks, then clindamycin 300 mg PO q6h x 6-12 months
Linezolid has the advantages of both suppressing toxin secretion and covering all Streptococcus and Staphylococcus (including all MRSA)
Call your healthcare provider right away if any of these symptoms occur
Complicated and uncomplicated skin and skin structure infection including diabetic foot ulcers (without
25–2 mg/L; and 11 penicillin-resistant, MIC ≥ 4 mg/L In the absence of intrapartum antibiotic prophylaxis, 1–2% of those newborns will develop GBS EOD 14 19
An earlier randomized, open-label, multicenter study of patients with DFIs compared linezolid to intravenous ampicillin-sulbactam and intravenous and oral amoxicillin-clavulanate (ratio of linezolid to comparator drug recipients, 2:1)
While more Linezolid has demonstrated potent in vitro activity against the vast majority of clinically important Gram-positive cocci, including VRE, as well as MRSA and high-level penicillin-resistant Streptococcus pneumoniae, which may potentially acquire resistance genes from enterococci
Tedizolid is a newer drug in the same class with comparable spectrum of activity but with limited US Food and Drug Administration-approved indications
In the United States, pneumonia is the second leading cause of hospitalization and is responsible for 5
Several mutations were present in the genome of Streptococcus pneumoniae linezolid-resistant strains but the role of several of these mutations had not been experimentally tested
In addition, fluoroquinolones carry risk of TABLE 2 lists oral antibiotics and their coverage of common bacteria involved in BSI
3 Linezolid was the first clinically applied member of the new antimicrobial class called the oxazolidinones